From: CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Cas protein | CRISPR system | Guide RNA | Nuclease activity | Recognition sequence on target | Reference |
---|---|---|---|---|---|
Cas9 | Type II | crRNA + transcrRNA | Yes | G-rich PAM | |
Cpf1 | Type V | crRNA | Yes | G-rich PAM | [46] |
Cas13a | Type VI-A | crRNA + transcrRNA | Yes | Except G-rich | [54] |
dCas9 | Type II | crRNA + transcrRNA | No | G-rich PAM | [140] |
Cas3 | Type I | crRNA | Yes | T-rich PAM | |
Cas10/Csm1 | Type III | crRNA | Yes | AT-rich PAM | |
dCas13a | Type VI-A | crRNA + transcrRNA | Yes | Except G-rich | [145] |